BIOTECH NEWS
Luminex Announces Commercial Launch of New Cystic Fibrosis Test
| Posted on August 27, 2010 at 10:59 AM |
comments (0)
|
Luminex Corporation (Nasdaq: LMNX), the worldwide leader in multiplexed solutions, today announced the full commercial launch of its xTAG(R) Cystic Fibrosis 60 Kit v2, a new diagnostic test that can simultaneously screen a single blood sample for up to 60 cystic fibrosis-causing gen...
Vanda Pharmaceuticals Initiates Phase III Clinical Study Aimed at Resetting the Body Clock
| Posted on August 27, 2010 at 10:55 AM |
comments (0)
|
Vanda Pharmaceuticals Inc. (Nasdaq: VNDA), today announced it has initiated a Phase III clinical trial to evaluate tasimelteon in patients with Non-24-Hour Sleep Wake Disorder (N24HSWD), a condition experienced primari...
Genentech Receives Refuse to File Letter from FDA for T-DM1
| Posted on August 27, 2010 at 10:40 AM |
comments (0)
|
Chelsea Therapeutics Announces FDA Approval of CH-4051 Phase II Protocol
| Posted on August 26, 2010 at 7:52 AM |
comments (0)
|
Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) announced confirmation by the U.S. Food and Drug Administration (FDA) that its proposed Phase II protocol for CH-4051 in rheumatoid arthritis has been approved by the agency. Chelsea plans to initiate patient screening next month and initiating treatment in October.
Read Full Post »
GSK Commences Phase 3 Clinical Trial with Shingles Vaccine Containing QS-21
| Posted on August 26, 2010 at 7:47 AM |
comments (0)
|
Antigenics, Inc. (NASDAQ : AGEN) today announced that GlaxoSmithKline’s (GSK) herpes zoster vacc...
Myriad Genetics to Present at the Morgan Stanley Global Healthcare Conference and the Stifel Nicolaus Healthcare Conference
| Posted on August 25, 2010 at 9:49 AM |
comments (0)
|
Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that Peter D. Meldrum, President and CEO, is scheduled to present at the Morgan Stanley Global Healthcare Conference, at 9:45 a.m. Eastern on September 14, 2010, at the Grand Hyatt Hotel in New York City and the Stifel Nicolaus Healthcare Confere...
Impax Pharmaceuticals Completes Enrollment in ADVANCE-PD Phase III Trial of IPX066 in Parkinson's Disease
| Posted on August 25, 2010 at 9:46 AM |
comments (0)
|
Impax Pharmaceuticals,the brand products division of Impax Laboratories, Inc. (NASDAQ: IPXL), today announced that it has completed enrollment of its ADVANCE-PD trial. ADVANCE-PD is a multinational Phase III trial of its late-stage product IPX066 in advan...
Data on VIVUS' Qnexa(R) to Be Presented at the European Society of Cardiology Congress
| Posted on August 25, 2010 at 9:43 AM |
comments (0)
|
VIVUS, Inc. (Nasdaq: VVUS) today announced that data on Qnexa(R), an investigational drug candidate, will be featured in two poster presentations at t...
Neuralstem Files FDA Application for First Chronic Spinal Cord Injury Stem Cell Trial
| Posted on August 25, 2010 at 9:40 AM |
comments (0)
|
Neuralstem, Inc. (NYSE Amex: CUR) announced that it has filed an Investigational New Drug (IND) application with the United States Food and Drug Administration (FDA) to begin a Phase I safety clinical trial for chro...
Celgene Expects to Receive a Paragraph IV Notification of an ANDA Filing for REVLIMID(R)
| Posted on August 25, 2010 at 9:35 AM |
comments (0)
|
Celgene Corporation (NASDAQ: CELG) today announced that information was posted on the FDA Web site indicating that an Abbreviated New Drug Application (ANDA) has been received by the Office of Generic Drugs (OGD) containing a "Paragraph IV" patent certification, for REVLI...
View Older Posts »
FDA and Biotech Events
Follow me
